跳至主要内容
临床试验/NCT00259558
NCT00259558已完成2 期

Prospektive, Randomisierte Doppelblinde Studie Zur Dosisfindung Von Intestinal Redardiert Freigesetztem Phosphatidylcholin Bei Chronisch Aktiver Pancolitis Ulcerosa

Heidelberg University1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2003年4月1日最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
60
试验地点
1
主要终点
Absolute change in clinical activity index (Rachmilewitz).

研究概览

简要总结

The purpose of this study is to find the optimal dose of retarded release Phosphatidylcholine in the most severe form of ulcerative colitis.

The hypothesis is that ulcerative colitis (UC) is caused by a barrier dysfunction of the colonic mucus layer. The background of the study is the finding, that the phosphatidylcholine (PC) content of the colonic mucus is strongly reduced in UC compared to healthy controls and patients with Crohn´s disease. The content was meuasured in non-inflamed areas of the colon in UC. Thus, we evaluate whether a substitution of colonic PC is an effective method.

详细描述

Design: prospective, randomized, double-blind, dose-finding study with retarded phosphatidylcholine.

Population: 10 patients per dose group (6 doses) - 60 patients Remark: this includes to historic groups from another study Inclusion criteria: Ulcerative Pancolitis with chronic active course and a clinical index (Rachmilewitz) over 7 and more, endoscopic index of at least 7 or more. No systemic steroids or immunosuppressants since 4 weeks.

Exclusion criteria: Pregnancy & fulminant course

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
16 Years 至 90 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • chronic active ulcerative pancolitis
  • course more than 4 months
  • clinical index rachmilewitz 7 or more
  • endoskopic index 7 or more

排除标准

  • steroids in the last 4 weeks
  • immunosuppressants in the last 4 weeks
  • use of topical klymsa
  • pregnancy
  • fulminant course
  • infectious colitis

结局指标

主要结局

Absolute change in clinical activity index (Rachmilewitz).

次要结局

  • Secondary end points include >50% changes in clinical and endoscopic activity index (EAI).
  • Histology and life quality are reported descriptively.

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验